Papadopoulos, Kyriakos P <br/><br/>
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.  [electronic resource] 

 -  Leukemia & lymphoma  Jun 2015 
 - 1763-70 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2014.974040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anemia--chemically induced<br/>Area Under Curve<br/>Diarrhea--chemically induced<br/>Drug Resistance, Neoplasm<br/>Exanthema--chemically induced<br/>Female<br/>Humans<br/>Lymphoma--drug therapy<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Nausea--chemically induced<br/>Neoplasm Recurrence, Local<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Quinoxalines--adverse effects<br/>Remission Induction<br/>Sulfonamides--adverse effects<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Treatment Outcome<br/>Young Adult